Cell wall synthesis inhibitors: Penicillins

61,762views

Cell wall synthesis inhibitors: Penicillins

PGreen

PGreen

Cell-cell junctions
Marfan syndrome
Cellular structure and function
Development of the renal system
Mitosis and meiosis
Colorectal polyps and cancer: Pathology review
Endometrial hyperplasia and cancer: Clinical
Lung cancer
Metaplasia and dysplasia
Oral cancer
Testicular cancer
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Arterial disease
Asthma
Atrial septal defect
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Angina pectoris
Aortic valve disease
Coarctation of the aorta
Heart failure
Pneumonia
Tetralogy of Fallot
Shock
Mitral valve disease
Pericarditis and pericardial effusion
Pleural effusion
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Anxiety disorders: Clinical
Arteriovenous malformation
Bipolar and related disorders
Cauda equina syndrome
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Panic disorder
Parkinson disease
Stroke: Clinical
Alzheimer disease
Diabetes mellitus: Pathology review
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Pelvic inflammatory disease
Testosterone
Polycystic ovary syndrome
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Thyroid hormones
Anemia of chronic disease
Chronic leukemia
Coagulation disorders: Pathology review
Disseminated intravascular coagulation
Factor V Leiden
Hemophilia
Non-Hodgkin lymphoma
Hypocalcemia
Hypokalemia
Inflammation
Innate immune system
Introduction to the immune system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Acute cholecystitis
Acute pancreatitis
Acute pyelonephritis
Alcohol-associated liver disease
Appendicitis
Autoimmune hepatitis
Biliary colic
Bowel obstruction
Chronic cholecystitis
Chronic pyelonephritis
Chronic pancreatitis
Cirrhosis
Congenital disorders: Clinical
Crohn disease
Gastroesophageal reflux disease (GERD)
Irritable bowel syndrome
Lower urinary tract infection
Nephrotic syndromes: Pathology review
Peptic ulcer
Renal failure: Pathology review
Ulcerative colitis
Urinary tract infections: Pathology review
Viral hepatitis
Acne vulgaris
Atopic dermatitis
Back pain: Pathology review
Bone disorders: Pathology review
Burns
Osteoarthritis
Osteoporosis
Paget disease of bone
Psoriasis
Rheumatoid arthritis
Skin cancer
Varicella zoster virus
Down syndrome (Trisomy 21)
Inheritance patterns
DNA damage and repair
DNA replication
Selective permeability of the cell membrane
Cell cycle
Free radicals and cellular injury
Autosomal trisomies: Pathology review
Breast cancer: Pathology review
Hypertension: Pathology review
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Peripheral artery disease
Pulmonary edema
Restrictive lung diseases
Stroke volume, ejection fraction, and cardiac output
Ventilation-perfusion ratios and V/Q mismatch
Cranial nerves
Migraine
Myasthenia gravis
Abnormal uterine bleeding: Clinical
Neisseria gonorrhoeae
Primary adrenal insufficiency
Benign prostatic hyperplasia
Hodgkin lymphoma
Introduction to the immune system
Celiac disease
Introduction to pharmacology
Drug administration and dosing regimens
Enzyme function
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
Opioid antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Vitamin B12 deficiency
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Adrenergic antagonists: Beta blockers
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class III antiarrhythmics: Potassium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Vaccinations
Anthelmintic medications
Anti-mite and louse medications
Antimalarials
Hepatitis medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Antihistamines for allergies
Miscellaneous antifungal medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Anti-parkinson medications
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Headaches: Clinical
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Antigout medications
Folate (Vitamin B9) deficiency
Vitamin D
Fat-soluble vitamin deficiency and toxicity: Pathology review
Mumps virus
Measles virus
Rubella virus
Bordetella pertussis (Whooping cough)
Poliovirus
Pediatric infectious rashes: Clinical

Flashcards

Cell wall synthesis inhibitors: Penicillins

0 of 53 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 5 complete

USMLE® Step 2 style questions USMLE

0 of 9 complete

A 40-year-old man comes to the office for the evaluation of a skin rash. It began a week ago on his trunk and has spread to his entire body now. He also reports low-grade fever, malaise, sore throat, and headache. The rest of the review of systems is unremarkable. He has had three female sexual partners over the past year. Past medical history is significant for type II diabetes mellitus managed with lifestyle modifications. Temperature is 37.2°C (99 F), pulse is 80/min, respirations are 17/min and blood pressure is 130/70 mm Hg. Physical examination shows a full-body maculopapular rash as shown below. Several gray, mucosal patches are seen in the mouth. Cervical, axillary and epitrochlear lymphadenopathy is present. HIV testing is negative. The patient is administered an intramuscular dose of penicillin G and sent home. He later presents to the emergency department three hours later with a worsening rash, muscle pain, rigors, and chills. His temperature is now 38.3°C (100.9 F), pulse is 80/min, respirations are 20/min and blood pressure is 100/60 mm Hg. Which of the following is the most likely cause of this patient’s current symptoms?


Reproduced from Flickr

Transcript

Watch video only

Penicillins are antibiotics that got their name from the Penicillium mold, from which they were originally extracted.

They belong to the pharmacological group of beta-lactam antibiotics.

What all beta-lactams have in common is a beta-lactam ring in their structure, which gives them their name, and also the mechanism of action - the inhibition of cell wall synthesis in bacteria.

So, our body consists of multiple eukaryotic cells, while bacterias are prokaryotic, meaning they are primitive, single cellular organisms.

Most have a slimy capsule made out of polysaccharides and a cell wall which encapsulates and protects the bacteria like a suit of armor and offers structural support.

Bacterial cell walls are made of a substance called peptidoglycan, or murein.

Peptidoglycan is a molecule composed out of long strands of amino polysaccharides running in parallel.

These are made of segments of N-acetylglucosamine, or NAG, and N-acetylmuramic acid, or NAM, in an alternating pattern - so, NAG, NAM, NAG, NAM, and so on, like a pearl necklace.

At the tips of the NAM subunits are tetrapeptide and pentapeptide chains, protruding from NAM subunits.

These peptide chains can link to other peptide chains from the neighboring strands through a process known as transpeptidation.

This is carried out by an enzyme called DD-transpeptidases, or penicillin binding proteins, or PBPs.

Now these enzymes are like locks and there are specific binding area for the pentapeptides keys to fit into.

Once the key goes in the lock, the PBP enzymes fuse them together, creating a stable link between the two amino polysaccharide strands and strengthen the cell wall.

In essence, all beta lactam antibiotics, like the penicillins, somewhat resemble the tetrapeptide chains.

Inside the bacteria, PBP enzymes will mistakenly bind to the beta lactams antibiotic molecule instead of a tetrapeptide and stick inside the PBP forever, like chewing gum in a keyhole, permanently disabling it.

As more and more of PBPs gets disabled, the crosslinking fails to occur, and the wall becomes weak and unstable.

If the affected bacteria attempts to divide, their cell wall will collapse, killing them in the process!

Now, some bacteria have developed resistance to beta lactam antibiotics.

The most notable is the notorious staphylococcus aureus, which evolved an enzyme called beta lactamases or penicillinases that breaks down the beta lactam ring within the antibiotic, rendering it ineffective.

In response, we started adding beta lactamase inhibitors, such as clavulanic acid, that would bind to beta lactamases and inactivate them, like the gum into the keyhole.

Another approach was to create new kinds of beta lactam antibiotics like methicillin, which has a large side chain that wouldn’t “fit” into the keyhole of the beta lactamase.

They did work quite well, until some staphylococcus aureus developed PBP site mutations that changed the shape of the keyhole.

So even if beta lactamase enzymes can’t break down these antibiotics, they won’t fit into the PBP enzyme and thus won’t work.

We call these bacteria methicillin resistant staphylococcus aureus, or MRSA.

This poses a huge problem, as it makes MRSA virtually untreatable by beta lactam antibiotics.

To treat MRSA, we resort to so-called reserve antibiotics belonging to the glycopeptide antibiotics, like vancomycin and teicoplanin.

But, even that might come to an end, as MRSA is also developing vancomycin resistance, becoming VRSA.

Now going back to penicillins, we can divide these medication into three main groups based on their spectrum of activity - which is how many different species of bacteria can they effectively treat, and how vulnerable are they to beta lactamases.

Examples of narrow spectrum, susceptible to beta lactamase medication are penicillin G, applied IV and penicillin V, applied perorally.

These are the classics, still quite usable against common gram positive bacteria like streptococcus pyogenes that cause pharyngitis, and gram negative bacteria like neisseria meningitidis, that causes, well, bacterial meningitis.

They are also effective against spirochetes - such as treponema pallidum, that causes syphilis, or borrelia burgdorferi, that causes Lyme disease.

They, however, do not work well against a lot of Gram negative aerobes, and some of the bacteria they used to treat well back in the day, like Staphylococcus aureus, strains of streptococcus pneumoniae, and recently, neisseria gonorrhoeae, have developed resistance.

Now, we want to make a simple and fun mnemonic that’ll help you efficiently memorize and retain all these crazy pharm facts! So imagine a street that’s wide at one end and very narrow at the other. We will put our narrow spectrum drugs right in the middle of the street, which is kind of narrow.

This group of drugs will be represented by an artistic “penda” holding a giant pen which represents penicillin.

His drawing will represent the bugs that this class of medication treats, which includes a large pie at the bottom for streptococcus pyogenes.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Methicillin-resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management" The American Journal of Medicine (1993)
  5. "Management of allergy to penicillins and other beta-lactams" Clinical & Experimental Allergy (2015)
  6. "Penicillins" Drugs (1993)
  7. "Antibiotic Resistance in Streptococcus pneumoniae" Clinical Infectious Diseases (1997)